Hanall Biopharma KRX:009420KOSPI
한올바이오파마 · Korean news coverage and regulatory filings, organized.
Articles, 24h2
Articles, 7 days16
DART filings, 7 days0
Articles tracked21since Sep 11
In Q2 2026, Hanall Biopharma reported revenue of ₩44.3bn, up 8.8% year on year, and operating profit of ₩5.6bn. Hanall Biopharma (한올바이오파마) appeared in 16 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 28 with 8 articles. The most common catalyst was risk & warnings (3). It was most often mentioned alongside Seojin System and KIWOOM Securities.
Filing signals Profit +50% Screener
Hanall Biopharma quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩44.3bn | +8.8% | ₩5.6bn margin 12.6% | −₩19.2bn |
| Q1 2026 | ₩40.0bn | +10.7% | ₩839m margin 2.1% | ₩275m |
| Q4 2025 derived | ₩37.5bn | +3.1% | −₩2.0bn margin −5.4% | −₩6.2bn |
| Q3 2025 | ₩40.8bn | +10.8% | ₩349m margin 0.9% | ₩299m |
| Q2 2025 | ₩40.7bn | +28.8% | ₩1.1bn margin 2.8% | ₩599m |
| Q1 2025 | ₩36.2bn | +6.0% | −₩394m margin −1.1% | −₩208m |
| Q4 2024 derived | ₩36.4bn | +14.8% | ₩2.7bn margin 7.5% | ₩1.6bn |
| Q3 2024 | ₩36.8bn | +11.7% | ₩430m margin 1.2% | ₩222m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Hanall Biopharma top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Hanall Biopharma news Korean headlines
-
Featured한올바이오파마, 파트너사 CLE 개발중단에 장초반 급락
1 more on this story · 1 outlets
- 한올바이오파마, 파트너사 CLE 개발중단에 6% 급락(종합)연합뉴스경제 · Sep 28 15:42